Quick Answer
TG THERAPEUTICS, INC. reported Research And Development Expense of $160.22 million for the year ending 2025.
- TG THERAPEUTICS, INC. showed an increase of +69.9% in Research And Development Expense from 2024 to 2025.
- This data is from TG THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $236.7 thousand | Q3 2011: $15.9 thousand | Q1 2012: $16.74 million | Q2 2012: $1.65 million | Q3 2012: $1.56 million | Q1 2013: $1.57 million | Q2 2013: $5.03 million | Q3 2013: $3.31 million | Q1 2014: $4.41 million | Q2 2014: $6.85 million | Q3 2014: $13.69 million | Q1 2015: $9.62 million | Q2 2015: $11.26 million | Q3 2015: $11.57 million | Q1 2016: $11.62 million | Q2 2016: $13.53 million | Q3 2016: $21.80 million | Q1 2017: $22.68 million | Q2 2017: $26.71 million | Q3 2017: $27.15 million | Q1 2018: $35.02 million | Q2 2018: $38.70 million | Q3 2018: $33.40 million | Q1 2019: $32.39 million | Q2 2019: $32.87 million | Q3 2019: $57.99 million | Q1 2020: $36.02 million | Q2 2020: $36.45 million | Q3 2020: $50.46 million | Q1 2021: $63.09 million | Q2 2021: $44.87 million | Q3 2021: $51.97 million | Q1 2022: $48.04 million | Q2 2022: $26.87 million | Q3 2022: $20.80 million | Q1 2023: $15.87 million | Q2 2023: $28.12 million | Q3 2023: $14.75 million | Q1 2024: $32.72 million | Q2 2024: $17.56 million | Q3 2024: $20.14 million | Q1 2025: $46.36 million | Q2 2025: $31.78 million | Q3 2025: $40.88 million.
- Over the full 15 years of available data (2011 to 2025), TG THERAPEUTICS, INC.'s Research And Development Expense has grown by 48,853.0%.
- Historical annual values: Fiscal year 2025: $160.22 million | Fiscal year 2024: $94.29 million | Fiscal year 2023: $76.19 million | Fiscal year 2022: $125.35 million | Fiscal year 2021: $222.58 million | Fiscal year 2020: $165.90 million | Fiscal year 2019: $154.18 million | Fiscal year 2018: $159.39 million | Fiscal year 2017: $102.53 million | Fiscal year 2016: $69.23 million | Fiscal year 2015: $47.71 million | Fiscal year 2014: $40.09 million | Fiscal year 2013: $13.66 million | Fiscal year 2012: $21.03 million | Fiscal year 2011: $327.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: